Cargando…

Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir

Background. Intensification of antiretroviral therapy with raltegravir does not affect levels of residual human immunodeficiency virus (HIV)-1 viremia, but it has led to increased levels of episomal HIV-1 DNA in some patients, suggesting antiviral activity against otherwise unresponsive components o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ouyang, Zhengyu, Buzon, Maria J., Zheng, Lu, Sun, Hong, Yu, Xu G., Bosch, Ronald J., Mellors, John W., Eron, Joseph J., Gandhi, Rajesh T., Lichterfeld, Mathias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567091/ https://www.ncbi.nlm.nih.gov/pubmed/26380343 http://dx.doi.org/10.1093/ofid/ofv045

Ejemplares similares

Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction
por: Ostrowski, Mario, et al.
Publicado: (2015)

The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
por: Gandhi, Rajesh T., et al.
Publicado: (2010)

Correction: The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
por: Gandhi, Rajesh T., et al.
Publicado: (2011)

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial
por: Kityo, Cissy, et al.
Publicado: (2018)

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
por: Castagna, Antonella, et al.
Publicado: (2014)

Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy
por: Delagreverie, Héloïse M, et al.
Publicado: (2020)

Comparative sensitivity of automated (Abbott M2000) and manual plasma HIV-1 RNA PCR assays for the detection of persistent viremia after long-term antiretroviral therapy
por: Tosiano, Melissa A., et al.
Publicado: (2022)

108. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy
por: Gandhi, Rajesh, et al.
Publicado: (2020)

Projected Benefits of Long-Acting Antiretroviral Therapy in Nonsuppressed People With Human Immunodeficiency Virus Experiencing Adherence Barriers
por: Chen, Wanyi, et al.
Publicado: (2023)

Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation
por: Gandhi, Rajesh T., et al.
Publicado: (2017)

Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race
por: Bhagwat, Priya, et al.
Publicado: (2018)

Household Contact Tracing With Intensified Tuberculosis and Human Immunodeficiency Virus Screening in South Africa: A Cluster-Randomized Trial( )
por: Martinson, Neil A, et al.
Publicado: (2021)

Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy
por: Li, Jonathan Z., et al.
Publicado: (2014)

Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life
por: Maswabi, Kenneth, et al.
Publicado: (2020)

Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s
por: Dirajlal-Fargo, Sahera, et al.
Publicado: (2016)

Modelling HIV-1 2-LTR dynamics following raltegravir intensification
por: Luo, Rutao, et al.
Publicado: (2013)

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
por: Cozzi‐Lepri, A, et al.
Publicado: (2017)

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
por: Gutierrez-Valencia, Alicia, et al.
Publicado: (2015)

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
por: Chirch, Lisa M, et al.
Publicado: (2010)

Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies
por: Squires, Kathleen, et al.
Publicado: (2017)

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
por: Eron, Joseph J., et al.
Publicado: (2013)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens
por: De La Cruz, Justin, et al.
Publicado: (2019)

Randomized Controlled Pilot Study of Antiretrovirals and a Behavioral Intervention for Persons With Acute HIV Infection: Opportunity for Interrupting Transmission
por: Miller, William C, et al.
Publicado: (2018)

Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) Trial
por: Baker, Jason V., et al.
Publicado: (2016)

Efficient HIV-1 Trans Infection of CD4(+) T Cells Occurs in the Presence of Antiretroviral Therapy
por: Rappocciolo, Giovanna, et al.
Publicado: (2019)

Antiretroviral Initiation at ≥800 CD4+ Cells/mm(3) Associated With Lower Human Immunodeficiency Virus Reservoir Size
por: Rasmussen, Thomas A, et al.
Publicado: (2022)

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART
por: Riddler, Sharon A, et al.
Publicado: (2018)

CD4 Variability in Malawi: Implications for Use of a CD4 Threshold of 500 Cells/mm(3) Versus Universal Eligibility for Antiretroviral Therapy
por: Schooley, Alan L., et al.
Publicado: (2016)

Potent Cell-Intrinsic Immune Responses in Dendritic Cells Facilitate HIV-1-Specific T Cell Immunity in HIV-1 Elite Controllers
por: Martin-Gayo, Enrique, et al.
Publicado: (2015)

HIV-1 persistence in CD4(+) T cells with stem cell-like properties
por: Buzon, Maria J., et al.
Publicado: (2014)

CD4 Recovery on Antiretroviral Therapy Is Associated With Decreased Progression to Liver Disease Among Hepatitis C Virus-Infected Injecting Drug Users
por: Anderson, Jeffrey P., et al.
Publicado: (2015)

Systemic Cytokine Levels Do Not Predict CD4(+) T-Cell Recovery After Suppressive Combination Antiretroviral Therapy in Chronic Human Immunodeficiency Virus Infection
por: Norris, Philip J., et al.
Publicado: (2016)

Cannabis Use Is Associated With Decreased Antiretroviral Therapy Adherence Among Older Adults With HIV
por: Manuzak, Jennifer A, et al.
Publicado: (2023)

T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy
por: Thomas, Allison S., et al.
Publicado: (2017)

Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption
por: Park, You Jeong, et al.
Publicado: (2017)

Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection
por: Archin, Nancie M., et al.
Publicado: (2010)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

A Qualitative Study of the Experience of Immediate Antiretroviral Therapy Among Urban Persons With Newly Diagnosed Human Immunodeficiency Virus
por: Christopoulos, Katerina A, et al.
Publicado: (2021)

HIV-Related Arterial Stiffness in Malawian Adults Is Associated With the Proportion of PD-1–Expressing CD8(+) T Cells and Reverses With Antiretroviral Therapy
por: Kelly, Christine, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i7iidip7nkovke340do562sedj